newsfilter
← Latest News
GlobeNewswire·

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pre-Commercial